Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

NCT02534935 ·Status: COMPLETED ·Phase: PHASE2

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

NCT00962624 ·Status: COMPLETED ·Phase: PHASE2

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

NCT01768117 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

NCT01830855 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

NCT01423084 ·Status: COMPLETED ·Phase: PHASE3

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

NCT01352793 ·Status: COMPLETED ·Phase: PHASE3

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

NCT02531698 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845 ·Status: COMPLETED ·Phase: PHASE3

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

NCT04825223 ·Status: TERMINATED ·Phase: PHASE1

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

NCT06314880 ·Status: RECRUITING ·Phase: PHASE1

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

NCT04318548 ·Status: COMPLETED ·Phase: PHASE3

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

NCT02305446 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

NCT00798304 ·Status: TERMINATED ·Phase: PHASE2

Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine

NCT02003313 ·Status: COMPLETED ·Phase: PHASE3

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

NCT03765073 ·Status: COMPLETED ·Phase: PHASE2

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

NCT01299480 ·Status: COMPLETED ·Phase: PHASE2

A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine

NCT02481232 ·Status: UNKNOWN ·Phase: PHASE1

Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

NCT01897402 ·Status: COMPLETED ·Phase: PHASE2

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

NCT01911221 ·Status: COMPLETED ·Phase: PHASE3

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

NCT01323270 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

NCT00248833 ·Status: COMPLETED ·Phase: PHASE1

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

NCT00297817 ·Status: COMPLETED ·Phase: PHASE2

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

NCT02106390 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults

NCT01478347 ·Status: COMPLETED ·Phase: PHASE3